title: Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.
abstract: BACKGROUND
  Nilotinib is a second-generation tyrosine kinase inhibitor that exhibits significant efficacy as first- or second-line treatment in patients with chronic myeloid leukemia (CML). We conducted a multicenter Phase II Clinical Trial to evaluate the safety and efficacy of nilotinib among Japanese patients with imatinib-resistant or -intolerant CML-chronic phase (CP) or accelerated phase (AP).
  
  
  RESULTS
  We analyzed 49 patients (33 imatinib-resistant and 16 imatinib-intolerant) treated with nilotinib 400 mg twice daily. The major molecular response (MMR) rate was 47.8% at 12 months among 35 patients who did not demonstrate an MMR at study entry. Somatic BCR-ABL1 mutations (Y253H, I418V, and exon 8/9 35-bp insertion [35INS]) were detected in 3 patients at 12 months or upon discontinuation of nilotinib. Although 75.5% of patients were still being treated at 12 months, nilotinib treatment was discontinued because of progressing disease in 1 patient, insufficient effect in 2, and adverse events in 9. There was no statistically significant correlation between MMR and trough concentrations of nilotinib. Similarly, no correlation was observed between trough concentrations and adverse events, except for pruritus and hypokalemia. Hyperbilirubinemia was frequently observed (all grades, 51.0%; grades 2-4, 29%; grades 3-4, 4.1%). Hyperbilirubinemia higher than grade 2 was significantly associated with the uridine diphosphate glucuronosyltransferase (UGT)1A9 I399C/C genotype (P = 0.0086; Odds Ratio, 21.2; 95% Confidence Interval 2.2-208.0).
  
  
  CONCLUSIONS
  Nilotinib was efficacious and well tolerated by patients with imatinib-resistant or -intolerant CML-CP/AP. Hyperbilirubinemia may be predicted before nilotinib treatment, and may be controlled by reducing the daily dose of nilotinib in patients with UGT1A9 polymorphisms.
  
  
  BACKGROUND
  clinicaltrials.gov: UMIN000002201.
authors.affiliation: Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543 Akita, Japan. naotot@doc.med.akita-u.ac.jp.
authors.forename: Naoto
authors.initials: N
authors.lastname: Takahashi
authors.forename: Masatomo
authors.initials: M
authors.lastname: Miura
authors.forename: Jun
authors.initials: J
authors.lastname: Kuroki
authors.forename: Kinuko
authors.initials: K
authors.lastname: Mitani
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kitabayashi
authors.forename: Osamu
authors.initials: O
authors.lastname: Sasaki
authors.forename: Hideo
authors.initials: H
authors.lastname: Kimura
authors.forename: Kiyotoshi
authors.initials: K
authors.lastname: Imai
authors.forename: Norifumi
authors.initials: N
authors.lastname: Tsukamoto
authors.forename: Hideyoshi
authors.initials: H
authors.lastname: Noji
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kondo
authors.forename: Mutsuhito
authors.initials: M
authors.lastname: Motegi
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kato
authors.forename: Masayuki
authors.initials: M
authors.lastname: Mita
authors.forename: Hajime
authors.initials: H
authors.lastname: Saito
authors.forename: Chikashi
authors.initials: C
authors.lastname: Yoshida
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Torimoto
authors.forename: Tomofumi
authors.initials: T
authors.lastname: Kimura
authors.forename: Yuji
authors.initials: Y
authors.lastname: Wano
authors.forename: Jun
authors.initials: J
authors.lastname: Nomura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Ko
authors.initials: K
authors.lastname: Mayama
authors.forename: Riko
authors.initials: R
authors.lastname: Honma
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Sugawara
authors.forename: Shinji
authors.initials: S
authors.lastname: Sato
authors.forename: Atsushi
authors.initials: A
authors.lastname: Shinagawa
authors.forename: Maiko
authors.initials: M
authors.lastname: Abumiya
authors.forename: Takenori
authors.initials: T
authors.lastname: Niioka
authors.forename: Hideo
authors.initials: H
authors.lastname: Harigae
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sawada